Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia

Acalabrutinib is a selective irreversible Bruton tyrosine kinase (BTK) inhibitor that does not affect IL2-associated tyrosine kinase or antibody-dependent cellular cytotoxicity, making it an attractive candidate for combination therapy with anti-CD20 antibodies. We investigated acalabrutinib plus ob...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Discov
Autori principali: Woyach, Jennifer A., Blachly, James S., Rogers, Kerry A., Bhat, Seema A., Jianfar, Mojgan, Lozanski, Gerard, Weiss, David M., Andersen, Barbara L., Gulrajani, Michael, Frigault, Melanie M., Hamdy, Ahmed, Izumi, Raquel, Munugalavadla, Veerendra, Quah, Cheng, Wang, Min-Hui, Byrd, John C.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8176161/
https://ncbi.nlm.nih.gov/pubmed/31915195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-19-1130
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi